NASDAQ
IMDX
Last Price
US $4.46
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
Insight Molecular Diagnostics Inc. cash flow to debt ratio of -634.37% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial risk - Healthy cash flow growth.
Insight Molecular Diagnostics Inc.'s free cash flow has decreased 19.50% from $-21.23M last year to $-25.37M, signaling decreasing performance
Financial risk - Healthy debt to equity ratio.
Insight Molecular Diagnostics Inc.'s debt to equity ratio is -0.29, signaling that the company spent its equity and risk bankruptcy.
Financial risk - Healthy debt to equity ratio development.
Insight Molecular Diagnostics Inc.'s debt to equity ratio is -0.29, signaling that the company spent its equity and risk bankruptcy.
Financial risk - Net debt/EBITDA.
Insight Molecular Diagnostics Inc. has negative EBITDA, making leverage ratio unreliable
Financial risk - ICR.
Insight Molecular Diagnostics Inc.'s interest coverage ratio is -399.72, which means that the company struggles to meet interest obligations, signaling financial risk.
Financial stability - Profit margin growth.
Insight Molecular Diagnostics Inc.'s profit margin has increased (-23.89%) in the last year from -3.23K% to -2.45K%, signaling increasing performance
Financial stability - Short term assets vs short term liabilities.
Insight Molecular Diagnostics Inc.'s short-term assets of $15.31M exceed its short-term liabilities of $12.07M
Decreasing performance - ROA.
Insight Molecular Diagnostics Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Increasing performance - Absolute return on equity.
Insight Molecular Diagnostics Inc.'s return on equity of 380.80%, is higher than 15.00%, indicating good performance
Decreasing performance - Earnings quality.
Insight Molecular Diagnostics Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
Insight Molecular Diagnostics Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings
Decreasing performance - Free cash flow.
Insight Molecular Diagnostics Inc. has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
Insight Molecular Diagnostics Inc. has negative free cash flow, indicating cash burn
Increasing performance - Healthy earnings growth.
Insight Molecular Diagnostics Inc.'s yearly earnings has increased -17.21% since last year from $-60.66M to $-50.22M, signaling increasing performance
Increasing performance - Healthy revenue growth.
Insight Molecular Diagnostics Inc.'s yearly revenue has increased 115.58% since last year from $1.88M to $4.05M, signaling increasing performance
Decreasing performance - ROIC.
ROIC -136.40% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Increasing performance - 3-year revenue CAGR.
Insight Molecular Diagnostics Inc.'s 3-year revenue CAGR of 61.76% is positive, indicating growing revenue over the past 3 years
Increasing performance - Revenue consistency.
Insight Molecular Diagnostics Inc. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance
Decreasing performance - ROE consistency.
Insight Molecular Diagnostics Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
Insight Molecular Diagnostics Inc. has insufficient data to evaluate this check.
Overvalued - Earnings yield.
Insight Molecular Diagnostics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
Insight Molecular Diagnostics Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Overvalued - EV/EBITDA.
Insight Molecular Diagnostics Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable
Overvalued - PEG ratio value.
Insight Molecular Diagnostics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - P/B ratio.
Insight Molecular Diagnostics Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails
Overvalued - P/S ratio.
Insight Molecular Diagnostics Inc. has a price-to-sales ratio of 78.94x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
380.80%
Return on equity
ROIC: -136.40%
Valuation History
-3.4X
Price to Earnings
EV/EBITDA: -2.5X
Cash flow
Profit margin
-8.61%
(FY vs FY)
Cash flow Y/Y
1.41%
(FY vs FY)
Fair Value
Market $4.46
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.